サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1463137

化学療法誘発性好中球減少症の治療市場、シェア、規模、動向、産業分析レポート：治療別、流通チャネル別、地域別

Chemotherapy Induced Neutropenia Treatment Market Share, Size, Trends, Industry Analysis Report, by Treatment, Distribution Channel; By Region;
出版日: | 発行: Polaris Market Research | ページ情報: 英文 114 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
化学療法誘発性好中球減少症の治療市場、シェア、規模、動向、産業分析レポート：治療別、流通チャネル別、地域別
出版日: 2024年03月24日
発行: Polaris Market Research
ページ情報: 英文 114 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

Polaris Market Research社の最新調査によると、世界の化学療法誘発性好中球減少症治療市場規模は2032年までに7億7,584万米ドルに達する見込みです。この調査レポートは、現在の市場力学を詳細に洞察し、将来の市場成長に関する分析を提供しています。

世界のがん罹患率の増加は、化学療法誘発性好中球減少症（CIN）治療市場の重要な促進要因となっています。がん罹患率上昇の主な要因は、急速に拡大する高齢化です。高齢化層は、遺伝子の突然変異、免疫システムの弱体化、発がん物質への長期暴露、DNA修復機構の障害、ホルモンの変動、加齢に伴う慢性疾患などの様々な要因により、がんに罹患しやすくなっています。

タバコの消費、座りっぱなしの習慣、食生活の乱れ、アルコールの過剰摂取など、不健康な生活習慣は、さらに世界のがん罹患率上昇の一因となっています。がんは依然として世界の主要死因であり、2020年だけでも約1,000万人の命を奪い、死亡者数のほぼ6人に1人を占める。最も罹患率の高いがんの種類は、乳がん（226万人）、肺がん（221万人）、結腸・直腸がん（193万人）、前立腺がん（141万人）、皮膚がん（120万人）、胃がん（109万人）です。さらに、年間約40万人の小児ががんと診断されています。

化学療法誘発性好中球減少症（CIN）は一般的に化学療法の副作用として起こり、感染症に対抗するのに不可欠な白血球の一種である好中球の数が減少します。化学療法薬は骨髄が好中球を生成する能力を妨げ、免疫系を弱め、感染症に対する脆弱性を高める。CINはしばしば治療の遅延や化学療法の減量につながり、治療効果に影響を及ぼします。

CINを経験した患者は重症感染症を発症するリスクが高まり、入院が必要となります。従って、化学療法誘発性好中球減少症の注意深いモニタリングと適切な管理は、合併症を最小限に抑え、がん治療を最適化するために不可欠です。このことは、CINに効果的に対処するためのオーダーメイドの治療アプローチに対する需要が高まっていることを強調しています。

世界のがん罹患率の上昇により、化学療法を受ける患者集団の増加が必要となり、その結果、化学療法誘発性好中球減少症（CIN）の効率的な管理に対する需要が高まっています。この需要の急増は、マーケット成長の主要な触媒として機能すると予想されます。さらに、より強力な標的療法のイントロダクションを含む化学療法プロトコルの進歩は、がん治療の有効性を高めています。しかし、こうした進展は同時にCINのリスクを高めています。その結果、化学療法患者における好中球減少症の予防と管理のための改善戦略の開発が急務となっています。

化学療法誘発性好中球減少症治療市場レポート・ハイライト

G-CSF製剤がゴールドスタンダード治療薬として最大シェアを獲得

病院薬局は設備と外科医を完備しているため、市場を独占

がん患者の増加と化学療法の使用により、APACは堅調な成長率を記録する見込み

主な市場参入企業は、AbbVie、Coherus BioSciences、GlaxoSmithKline、Lupin、G1 Therapeutics、Merck、Novartis、Spectrum Pharmaceuticalsなどです。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 調査手法

第4章 世界の化学療法誘発性好中球減少症（CIN）治療市場の洞察

  • 化学療法誘発性好中球減少症（CIN）治療市場- 業界スナップショット
  • 化学療法誘発性好中球減少症（CIN）治療市場力学
    • 促進要因と機会
      • がん患者数の増加と治療選択肢としての化学療法の利用増加
      • 化学療法誘発性好中球減少症の可能性の上昇
    • 抑制要因と課題
      • 治療費の高騰と厳しい規制政策
  • PESTLE分析
  • 化学療法誘発性好中球減少症（CIN）治療業界の動向
  • バリューチェーン分析
  • COVID-19の影響分析

第5章 化学療法誘発性好中球減少症（CIN）治療の世界市場、治療タイプ別

  • 主な調査結果
  • イントロダクション
  • 抗生物質療法
  • 顆粒球コロニー刺激因子療法（G-CSF）
  • 顆粒球輸血
  • その他

第6章 世界の化学療法誘発性好中球減少症（CIN）治療市場、流通チャネル別

  • 主な調査結果
  • イントロダクション
  • 病院薬局
  • 小売薬局
  • オンライン薬局

第7章 世界の化学療法誘発性好中球減少症（CIN）治療市場、地域別

  • 主な調査結果
  • イントロダクション
    • 化学療法誘発性好中球減少症（CIN）治療市場の評価、地域別、2019年～2032年
  • 化学療法誘発性好中球減少症（CIN）治療市場-北米
    • 北米：化学療法誘発性好中球減少症（CIN）治療市場、流通チャネル別、2019年～2032年
    • 北米：化学療法誘発性好中球減少症（CIN）治療市場、治療タイプ別、2019年～2032年
    • 化学療法誘発性好中球減少症（CIN）治療市場-米国
    • 化学療法誘発性好中球減少症（CIN）治療市場- カナダ
  • 化学療法誘発性好中球減少症（CIN）治療市場- 欧州
    • 欧州：化学療法誘発性好中球減少症（CIN）治療市場、流通チャネル別、2019年～2032年
    • 欧州：化学療法誘発性好中球減少症（CIN）治療市場、治療タイプ別、2019年～2032年
    • 化学療法誘発性好中球減少症（CIN）治療市場- 英国
    • 化学療法誘発性好中球減少症（CIN）治療市場- フランス
    • 化学療法誘発性好中球減少症（CIN）治療市場- ドイツ
    • 化学療法誘発性好中球減少症（CIN）治療市場- イタリア
    • 化学療法誘発性好中球減少症（CIN）治療市場- スペイン
    • 化学療法誘発性好中球減少症（CIN）治療市場- オランダ
    • 化学療法誘発性好中球減少症（CIN）治療市場- ロシア
  • 化学療法誘発性好中球減少症（CIN）治療市場- アジア太平洋
    • アジア太平洋：化学療法誘発性好中球減少症（CIN）治療市場、流通チャネル別、2019年～2032年
    • アジア太平洋：化学療法誘発性好中球減少症（CIN）治療市場、治療タイプ別、2019年～2032年
    • 化学療法誘発性好中球減少症（CIN）治療市場- 中国
    • 化学療法誘発性好中球減少症（CIN）治療市場- インド
    • 化学療法誘発性好中球減少症（CIN）治療市場- マレーシア
    • 化学療法誘発性好中球減少症（CIN）治療市場- 日本
    • 化学療法誘発性好中球減少症（CIN）治療市場- インドネシア
    • 化学療法誘発性好中球減少症（CIN）治療市場- 韓国
  • 化学療法誘発性好中球減少症（CIN）治療市場-中東・アフリカ
    • 中東・アフリカ：化学療法誘発性好中球減少症（CIN）治療市場、流通チャネル別、2019年～2032年
    • 中東・アフリカ：化学療法誘発性好中球減少症（CIN）治療市場、治療タイプ別、2019年～2032年
    • 化学療法誘発性好中球減少症（CIN）治療市場- サウジアラビア
    • 化学療法誘発性好中球減少症（CIN）治療市場-UAE
    • 化学療法誘発性好中球減少症（CIN）治療市場- イスラエル
    • 化学療法誘発性好中球減少症（CIN）治療市場- 南アフリカ
  • 化学療法誘発性好中球減少症（CIN）治療市場-ラテンアメリカ
    • ラテンアメリカ：化学療法誘発性好中球減少症（CIN）治療市場、流通チャネル別、2019年～2032年
    • ラテンアメリカ：化学療法誘発性好中球減少症（CIN）治療市場、治療タイプ別、2019年～2032年
    • 化学療法誘発性好中球減少症（CIN）治療市場- メキシコ
    • 化学療法誘発性好中球減少症（CIN）治療市場- ブラジル
    • 化学療法誘発性好中球減少症（CIN）治療市場- アルゼンチン

第8章 競合情勢

  • 拡大と買収の分析
    • 拡大
    • 買収
  • パートナーシップ/コラボレーション/契約/展示会

第9章 企業プロファイル

  • AbbVie Inc.（Allergan PLC）
  • Aurobindo Pharma
  • Coherus BioSciences
  • GlaxoSmithKline PLC.
  • Lupin, G1 Therapeutics, Inc
  • Merck & Co., Inc
  • Novartis AG
  • Spectrum Pharmaceuticals
図表

List of Tables

  • Table 1 Global Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 2 Global Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
  • Table 3 Chemotherapy Induced Neutropenia (CIN) Treatment Market Assessment, By Geography, 2019-2032 (USD Million)
  • Table 4 North America: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 5 North America: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
  • Table 6 U.S.: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 7 U.S.: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
  • Table 8 Canada: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 9 Canada: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
  • Table 10 Europe: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 11 Europe: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
  • Table 12 UK: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 13 UK: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
  • Table 14 France: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 15 France: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
  • Table 16 Germany: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 17 Germany: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
  • Table 18 Italy: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 19 Italy: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
  • Table 20 Spain: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 21 Spain: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
  • Table 22 Netherlands: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 23 Netherlands: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
  • Table 24 Russia: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 25 Russia: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
  • Table 26 Asia Pacific: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 27 Asia Pacific: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
  • Table 28 China: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 29 China: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
  • Table 30 India: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 31 India: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
  • Table 32 Malaysia: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 33 Malaysia: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
  • Table 34 Japan: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 35 Japan: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
  • Table 36 Indonesia: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 37 Indonesia: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
  • Table 38 South Korea: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 39 South Korea: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
  • Table 40 Middle East & Africa: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 41 Middle East & Africa: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
  • Table 42 Saudi Arabia: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 43 Saudi Arabia: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
  • Table 44 UAE: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 45 UAE: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
  • Table 46 Israel: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 47 Israel: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
  • Table 48 South Africa: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 49 South Africa: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
  • Table 50 Latin America: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 51 Latin America: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
  • Table 52 Mexico: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 53 Mexico: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
  • Table 54 Brazil: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 55 Brazil: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
  • Table 56 Argentina: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 57 Argentina: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)

List of Figures

  • Figure 1 Global Chemotherapy Induced Neutropenia (CIN) Treatment Market, 2019-2032 (USD Million)
  • Figure 2 Integrated Ecosystem
  • Figure 3 Research Methodology: Top-Down & Bottom-Up Approach
  • Figure 4 Market by Geography
  • Figure 5 Porter's Five Forces
  • Figure 6 Market by Distribution Channel
  • Figure 7 Global Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2022 & 2032 (USD Million)
  • Figure 8 Market by Treatment Type
  • Figure 9 Global Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2022 & 2032 (USD Million)
  • Figure 10 Chemotherapy Induced Neutropenia (CIN) Treatment Market Assessment, By Geography, 2019-2032 (USD Million)
  • Figure 11 Strategic Analysis - Chemotherapy Induced Neutropenia (CIN) Treatment Market
目次
Product Code: PM4799

The global chemotherapy induced neutropenia treatment market size is expected to reach USD 775.84 million by 2032, according to a new study by Polaris Market Research. The report "Chemotherapy Induced Neutropenia (CIN) Treatment Market Share, Size, Trends, Industry Analysis Report, by Treatment (Antibiotic Therapy, Granulocyte Colony-Stimulating Factor Therapy, Granulocyte Transfusion, and Others), Distribution Channel; By Region; Segment Forecast, 2024- 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The increasing global incidence of cancer serves as a significant driver for the chemotherapy-induced neutropenia (CIN) treatment market. A major contributing factor to the rising cancer rates is the rapidly expanding aging population. The aging demographic is more susceptible to cancer due to various factors such as genetic mutations, weakened immune systems, prolonged exposure to carcinogens, impaired DNA repair mechanisms, hormonal fluctuations, and age-related chronic ailments.

Unhealthy lifestyle behaviours, including tobacco consumption, sedentary habits, poor dietary choices, and excessive alcohol intake, further contribute to the escalating cancer incidence worldwide. Cancer remains a leading cause of death globally, claiming nearly 10 Mn lives in 2020 alone, which accounts for nearly one in six deaths. The most prevalent cancer types include breast cancer (2.26 Mn cases), lung cancer (2.21 Mn), colon and rectal cancer (1.93 Mn cases), prostate cancer (1.41 Mn), skin cancer (1.20 Mn), and stomach cancer (1.09 Mn). Additionally, approximately 400,000 children are diagnosed with cancer annually.

Chemotherapy-induced neutropenia (CIN) commonly occurs as a side effect of chemotherapy, wherein the number of neutrophils, a type of white blood cell vital for combating infections, decreases. Chemotherapy medications hinder the bone marrow's ability to generate neutrophils, weakening the immune system and heightening vulnerability to infections. CIN often leads to treatment delays or reductions in chemotherapy dosage, impacting treatment effectiveness.

Patients experiencing CIN face a heightened risk of developing severe infections, necessitating hospitalization. Consequently, careful monitoring and appropriate management of chemotherapy-induced neutropenia are essential to minimize complications and optimize cancer treatment delivery. This underscores the increasing demand for tailored treatment approaches to address CIN effectively.

The rising global cancer rates have necessitated a larger cohort of patients undergoing chemotherapy, consequently escalating the demand for efficient management of chemotherapy-induced neutropenia (CIN). This surge in demand is anticipated to serve as a primary catalyst for the growth of the market. Furthermore, advancements in chemotherapy protocols, including the introduction of more potent and targeted therapies, have enhanced cancer treatment efficacy. However, these developments have concurrently heightened the risk of CIN. Consequently, there is an increased urgency to develop improved strategies for the prevention and management of neutropenia in chemotherapy patients.

Chemotherapy Induced Neutropenia Treatment Market Report Highlights

G-CSF segment garnered the largest share, as it is considered as gold standard treatment option

Hospital pharmacies dominated the market, as they are fully equipped with the facilities and surgeons

APAC expected to register robust growth rate, owing to the rise in cancer cases and use of chemotherapy

The key market players include AbbVie, Coherus BioSciences, GlaxoSmithKline, Lupin, G1 Therapeutics, Merck, Novartis, and Spectrum Pharmaceuticals

Polaris Market Research has segmented the chemotherapy induced neutropenia treatment market report based on treatment type, distribution channel, and region:

Chemotherapy Induced Neutropenia Treatment Market, Type Outlook (Revenue - USD Million, 2023 - 2032)

  • Antibiotic Therapy
  • Granulocyte Colony-Stimulating Factor Therapy (G-CSF)
  • Granulocyte Transfusion
  • Others

Chemotherapy Induced Neutropenia Treatment Market, Distribution Channel Outlook (Revenue - USD Million, 2023 - 2032)

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Chemotherapy Induced Neutropenia Treatment Market, Regional Outlook (Revenue - USD Million, 2023 - 2032)

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Rest of Asia Pacific
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Rest of Latin America
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa
  • Rest of Middle East & Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Chemotherapy Induced Neutropenia (CIN) Treatment Market Insights

  • 4.1. Chemotherapy Induced Neutropenia (CIN) Treatment Market - Industry Snapshot
  • 4.2. Chemotherapy Induced Neutropenia (CIN) Treatment Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Rising cases of cancer and increasing use of chemotherapy as treatment option
      • 4.2.1.2. Rising likelihood of chemotherapy induced neutropenia
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. High cost of treatment and stringent regulatory policies
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTLE Analysis
  • 4.5. Chemotherapy Induced Neutropenia (CIN) Treatment Industry trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Chemotherapy Induced Neutropenia (CIN) Treatment, by Treatment Type, 2019-2032 (USD Million)
  • 5.3. Antibiotic Therapy
    • 5.3.1. Global Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Antibiotic Therapy, by Region, 2019-2032 (USD Million)
  • 5.4. Granulocyte Colony-Stimulating Factor Therapy (G-CSF)
    • 5.4.1. Global Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Granulocyte Colony-Stimulating Factor Therapy (G-CSF), by Region, 2019-2032 (USD Million)
  • 5.5. Granulocyte Transfusion
    • 5.5.1. Global Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Granulocyte Transfusion, by Region, 2019-2032 (USD Million)
  • 5.6. Others
    • 5.6.1. Global Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Others, by Region, 2019-2032 (USD Million)

6. Global Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • 6.3. Hospital Pharmacies
    • 6.3.1. Global Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Hospital Pharmacies, by Region, 2019-2032 (USD Million)
  • 6.4. Retail Pharmacies
    • 6.4.1. Global Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Retail Pharmacies, by Region, 2019-2032 (USD Million)
  • 6.5. Online Pharmacies
    • 6.5.1. Global Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Online Pharmacies, by Region, 2019-2032 (USD Million)

7. Global Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Geography

  • 7.1. Key findings
  • 7.2. Introduction
    • 7.2.1. Chemotherapy Induced Neutropenia (CIN) Treatment Market Assessment, By Geography, 2019-2032 (USD Million)
  • 7.3. Chemotherapy Induced Neutropenia (CIN) Treatment Market - North America
    • 7.3.1. North America: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
    • 7.3.2. North America: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
    • 7.3.3. Chemotherapy Induced Neutropenia (CIN) Treatment Market - U.S.
      • 7.3.3.1. U.S.: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 7.3.3.2. U.S.: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
    • 7.3.4. Chemotherapy Induced Neutropenia (CIN) Treatment Market - Canada
      • 7.3.4.1. Canada: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 7.3.4.2. Canada: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
  • 7.4. Chemotherapy Induced Neutropenia (CIN) Treatment Market - Europe
    • 7.4.1. Europe: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
    • 7.4.2. Europe: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
    • 7.4.3. Chemotherapy Induced Neutropenia (CIN) Treatment Market - UK
      • 7.4.3.1. UK: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 7.4.3.2. UK: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
    • 7.4.4. Chemotherapy Induced Neutropenia (CIN) Treatment Market - France
      • 7.4.4.1. France: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 7.4.4.2. France: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
    • 7.4.5. Chemotherapy Induced Neutropenia (CIN) Treatment Market - Germany
      • 7.4.5.1. Germany: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 7.4.5.2. Germany: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
    • 7.4.6. Chemotherapy Induced Neutropenia (CIN) Treatment Market - Italy
      • 7.4.6.1. Italy: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 7.4.6.2. Italy: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
    • 7.4.7. Chemotherapy Induced Neutropenia (CIN) Treatment Market - Spain
      • 7.4.7.1. Spain: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 7.4.7.2. Spain: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
    • 7.4.8. Chemotherapy Induced Neutropenia (CIN) Treatment Market - Netherlands
      • 7.4.8.1. Netherlands: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 7.4.8.2. Netherlands: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
    • 7.4.9. Chemotherapy Induced Neutropenia (CIN) Treatment Market - Russia
      • 7.4.9.1. Russia: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 7.4.9.2. Russia: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
  • 7.5. Chemotherapy Induced Neutropenia (CIN) Treatment Market - Asia Pacific
    • 7.5.1. Asia Pacific: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
    • 7.5.2. Asia Pacific: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
    • 7.5.3. Chemotherapy Induced Neutropenia (CIN) Treatment Market - China
      • 7.5.3.1. China: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 7.5.3.2. China: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
    • 7.5.4. Chemotherapy Induced Neutropenia (CIN) Treatment Market - India
      • 7.5.4.1. India: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 7.5.4.2. India: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
    • 7.5.5. Chemotherapy Induced Neutropenia (CIN) Treatment Market - Malaysia
      • 7.5.5.1. Malaysia: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 7.5.5.2. Malaysia: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
    • 7.5.6. Chemotherapy Induced Neutropenia (CIN) Treatment Market - Japan
      • 7.5.6.1. Japan: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 7.5.6.2. Japan: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
    • 7.5.7. Chemotherapy Induced Neutropenia (CIN) Treatment Market - Indonesia
      • 7.5.7.1. Indonesia: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 7.5.7.2. Indonesia: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
    • 7.5.8. Chemotherapy Induced Neutropenia (CIN) Treatment Market - South Korea
      • 7.5.8.1. South Korea: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 7.5.8.2. South Korea: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
  • 7.6. Chemotherapy Induced Neutropenia (CIN) Treatment Market - Middle East & Africa
    • 7.6.1. Middle East & Africa: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
    • 7.6.2. Middle East & Africa: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
    • 7.6.3. Chemotherapy Induced Neutropenia (CIN) Treatment Market - Saudi Arabia
      • 7.6.3.1. Saudi Arabia: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 7.6.3.2. Saudi Arabia: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
    • 7.6.4. Chemotherapy Induced Neutropenia (CIN) Treatment Market - UAE
      • 7.6.4.1. UAE: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 7.6.4.2. UAE: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
    • 7.6.5. Chemotherapy Induced Neutropenia (CIN) Treatment Market - Israel
      • 7.6.5.1. Israel: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 7.6.5.2. Israel: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
    • 7.6.6. Chemotherapy Induced Neutropenia (CIN) Treatment Market - South Africa
      • 7.6.6.1. South Africa: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 7.6.6.2. South Africa: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
  • 7.7. Chemotherapy Induced Neutropenia (CIN) Treatment Market - Latin America
    • 7.7.1. Latin America: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
    • 7.7.2. Latin America: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
    • 7.7.3. Chemotherapy Induced Neutropenia (CIN) Treatment Market - Mexico
      • 7.7.3.1. Mexico: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 7.7.3.2. Mexico: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
    • 7.7.4. Chemotherapy Induced Neutropenia (CIN) Treatment Market - Brazil
      • 7.7.4.1. Brazil: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 7.7.4.2. Brazil: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
    • 7.7.5. Chemotherapy Induced Neutropenia (CIN) Treatment Market - Argentina
      • 7.7.5.1. Argentina: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 7.7.5.2. Argentina: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)

8. Competitive Landscape

  • 8.1. Expansion and Acquisition Analysis
    • 8.1.1. Expansion
    • 8.1.2. Acquisitions
  • 8.2. Partnerships/Collaborations/Agreements/Exhibitions

9. Company Profiles

  • 9.1. AbbVie Inc. (Allergan PLC)
    • 9.1.1. Company Overview
    • 9.1.2. Financial Performance
    • 9.1.3. Product Benchmarking
    • 9.1.4. Recent Development
  • 9.2. Aurobindo Pharma
    • 9.2.1. Company Overview
    • 9.2.2. Financial Performance
    • 9.2.3. Product Benchmarking
    • 9.2.4. Recent Development
  • 9.3. Coherus BioSciences
    • 9.3.1. Company Overview
    • 9.3.2. Financial Performance
    • 9.3.3. Product Benchmarking
    • 9.3.4. Recent Development
  • 9.4. GlaxoSmithKline PLC.
    • 9.4.1. Company Overview
    • 9.4.2. Financial Performance
    • 9.4.3. Product Benchmarking
    • 9.4.4. Recent Development
  • 9.5. Lupin, G1 Therapeutics, Inc
    • 9.5.1. Company Overview
    • 9.5.2. Financial Performance
    • 9.5.3. Product Benchmarking
    • 9.5.4. Recent Development
  • 9.6. Merck & Co., Inc
    • 9.6.1. Company Overview
    • 9.6.2. Financial Performance
    • 9.6.3. Product Benchmarking
    • 9.6.4. Recent Development
  • 9.7. Novartis AG
    • 9.7.1. Company Overview
    • 9.7.2. Financial Performance
    • 9.7.3. Product Benchmarking
    • 9.7.4. Recent Development
  • 9.8. Spectrum Pharmaceuticals
    • 9.8.1. Company Overview
    • 9.8.2. Financial Performance
    • 9.8.3. Product Benchmarking
    • 9.8.4. Recent Development